The Pandemic, the Media, and Restoring Trust in Science

Published June 28, 2023

The American media is biased toward negative news reporting, which resulted in a distorted view of the actual risk of COVID-19. Worse still, social media companies censored many truthful posts under the guise of misinformation. The inevitable result of this media distortion has been the destruction of the trust in American institutions and experts.

Discussion Questions:

  1. What are the right public policy lessons from the pandemic, and have we learned them?
  2. Has science been taken over by politics? If so, what should be done to fix that?

Additional Resources:

  • Read Scott Atlas’s book A Plague upon Our House: My Fight at the Trump White House to Stop COVID from Destroying America. Available here.
  • Read “During COVID, the More Prestigious the College, the Lower the Quality of Education,” by Paul Peterson, John Schoof, and Jay Greene via The Hill. Available here.
  • Watch “An Endless Summer: How COVID Has Reversed Academic Achievement,” with Macke Raymond on PolicyEd. Available here.

Cast

Scott W. Atlas

Scott W. Atlas

Related

Articles

Seven Policies To Reduce Medicare Spending And Shrink The Federal Deficit

We asked Medicare policy experts to write up proposals that save taxpayers ~$100 billion over ten years. Here’s what they came up with.

October 20, 2026

Modernizing Medicare Cost Sharing

Traditional Medicare’s cost-sharing structure has not changed since 1965. Beneficiaries face separate Part A and Part B deductibles, per-day hospital copays, no coinsurance on certain services, and no annual out-of-pocket cap. This brief lays out reform templates proposed by the Simpson-Bowles Commission, the Congressional Budget Office, and others, compares a decade of budget scores, and analyzes a pending Senate bill that would add a spending cap without the offsetting cost-saving reforms.

October 20, 2026

Reforming the 340B Drug Pricing Program

The federal 340B drug pricing program lets hospitals buy outpatient drugs at steep discounts and keep the difference when insurers pay full price. It requires no proof that the savings reach low-income patients. The program rewards costlier drugs, drives hospital acquisitions of independent physician practices, and pushes clinics into wealthier neighborhoods. This brief proposes ending 340B discounts for hospitals and replacing them with a patient-centered fund financed by drug manufacturers.

October 20, 2026